Pharmacokinetics of intermittent dosed intravenous vancomycin in adult persons with cystic fibrosis
Sign Up to like & getrecommendations! Published in 2022 at "Pediatric Pulmonology"
DOI: 10.1002/ppul.26077
Abstract: Antibiotics have altered pharmacokinetics (PK) in persons with cystic fibrosis (PwCF) during treatment for an acute pulmonary exacerbation (APE). The Cystic Fibrosis Foundation Pulmonary Guidelines–Treatment of Pulmonary Exacerbations do not provide specific recommendations for treatment… read more here.
Keywords: intermittent; persons cystic; intravenous vancomycin; vancomycin adult ... See more keywords
Breath biomarkers associated with nontuberculosis mycobacteria disease status in persons with cystic fibrosis: a pilot study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Breath Research"
DOI: 10.1088/1752-7163/ac6bb6
Abstract: Pulmonary infections caused by mycobacteria cause significant mortality and morbidity in the human population. Diagnosing mycobacterial infections is challenging. An infection can lead to active disease or remain indolent with little clinical consequence. In patients… read more here.
Keywords: cystic fibrosis; persons cystic; disease; disease status ... See more keywords
Using metabolic potential within the airway microbiome as predictors of clinical state in persons with cystic fibrosis
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2022.1082125
Abstract: Introduction Pulmonary exacerbations (PEx) in persons with cystic fibrosis (CF) are primarily related to acute or chronic inflammation associated with bacterial lung infections, which may be caused by several bacteria that activate similar bacterial genes… read more here.
Keywords: persons cystic; bacterial species; clinical state; airway microbiome ... See more keywords